This problem is easily transmitted through air and through direct contact with the infected person. Chickenpox can be also transmitted from the pregnant mother to the unborn child.



The most common symptoms developed in chickenpox are fever, aches and pain, headache, sore throat, blisters and rash. It is good to know that these symptoms are not seen in every person. Each individual develops different symptoms and only in rare cases one individual experiences all of them.

The most common way of prevention for chickenpox is the vaccine. Even if it was proved that the vaccine is efficient in about 70 to 90 % of the cases it was also noticed that even if they develop chickenpox, the vaccinated persons experience milder symptoms.

The special cases such as children with kidney disease should be treated separately. It was proved that two doses of varicella vaccine should be safe and in the same time effective for children with chronic kidney disease. The vaccine should be taken one to two months apart.

The results are not encouraging as they seem. Studies proved that for children who would like to undergo for a kidney transplant there is a high risk for severe chickenpox complications, including pneumonia, brain inflammation and even death.

Specialists recommend chickenpox vaccination to be included as a component of pre-end-stage renal disease and end-stage renal disease care.

The varicella vaccine contains small doses of weakened of the chickenpox virus that activate the immune system and mount a response for further threats.

For children that are younger than 12 years, vaccination in a single dose is believed to be enough, while for adolescents two doses are recommended. If children with weakened immune systems are not vaccinated then serious problems might occur.

A study identified 96 children with chronic kidney disease and with no history in chickenpox. They were all vaccinated with two injections of varicella vaccine, four to eight weeks apart.

It was noticed that one child developed chickenpox. Eleven of these children developed a rash that was associated with the vaccine and seven of them reported a mild redness or soreness at the site of injection.

In three years after the study began, researchers reported each child, including those that received a kidney transplant. The conclusion was that 87 % retained the antibody levels for the three years of research. It was also proved that even if the levels of antibodies lowered after the kidney transplant, in time these levels increased.